Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Scuffham

Showing results (1-10 of 208) with videos related to

Pageof 21
Sort By:
Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention|August 5, 2008
Cost-effectiveness analyses for injury prevention initiatives in low- and middle-income countriesPaul A Scuffham
Vaccine|July 13, 2004
Estimating influenza-related hospital admissions in older people from GP consultation dataPaul A Scuffham
Evidence-Based Cardiovascular Medicine|December 29, 2005
Nurse-led primary care clinics for the secondary prevention of heart disease appear cost-effective compared to usual care. CommentaryPaul A Scuffham
Current Medical Research and Opinion|June 12, 2008
The cost-effectiveness of thrombolysis administered by paramedicsPaul A Scuffham, Vivienne Tippett
Pharmacoeconomics|June 26, 2004
An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UKPaul A Scuffham, Stephen Chaplin
Cardiovascular Drugs and Therapy|June 17, 2006
The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary interventionPaul A Scuffham, József Kósa
Clinical Therapeutics|November 18, 2005
A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary interventionPaul A Scuffham, Stephen Chaplin
Australian and New Zealand Journal of Public Health|December 14, 2011
Uncertainty and variability in influenza cost-effectiveness modelsAnthony T Newall, Paul A Scuffham
Vaccine|October 23, 2008
Influenza-related disease: the cost to the Australian healthcare systemAnthony T Newall, Paul A Scuffham
Applied Health Economics and Health Policy|November 19, 2003
Economics and decisions to end life: van Acht and Stooker revisitedPaul A Scuffham, Matthew J Taylor
Pageof 21

Showing results (1-10 of 208) with videos related to

Sort By:
Pageof 21
Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention|August 5, 2008
Cost-effectiveness analyses for injury prevention initiatives in low- and middle-income countriesPaul A Scuffham
Vaccine|July 13, 2004
Estimating influenza-related hospital admissions in older people from GP consultation dataPaul A Scuffham
Evidence-Based Cardiovascular Medicine|December 29, 2005
Nurse-led primary care clinics for the secondary prevention of heart disease appear cost-effective compared to usual care. CommentaryPaul A Scuffham
Current Medical Research and Opinion|June 12, 2008
The cost-effectiveness of thrombolysis administered by paramedicsPaul A Scuffham, Vivienne Tippett
Pharmacoeconomics|June 26, 2004
An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UKPaul A Scuffham, Stephen Chaplin
Cardiovascular Drugs and Therapy|June 17, 2006
The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary interventionPaul A Scuffham, József Kósa
Clinical Therapeutics|November 18, 2005
A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary interventionPaul A Scuffham, Stephen Chaplin
Australian and New Zealand Journal of Public Health|December 14, 2011
Uncertainty and variability in influenza cost-effectiveness modelsAnthony T Newall, Paul A Scuffham
Vaccine|October 23, 2008
Influenza-related disease: the cost to the Australian healthcare systemAnthony T Newall, Paul A Scuffham
Applied Health Economics and Health Policy|November 19, 2003
Economics and decisions to end life: van Acht and Stooker revisitedPaul A Scuffham, Matthew J Taylor
Pageof 21